Leila Dorling

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7762399/publications.pdf Version: 2024-02-01



LEUA DORUNG

#	Article	IF	CITATIONS
1	Breast Cancer Risk Genes — Association Analysis in More than 113,000 Women. New England Journal of Medicine, 2021, 384, 428-439.	27.0	532
2	Cancer Risks Associated With Germline <i>PALB2</i> Pathogenic Variants: An International Study of 524 Families. Journal of Clinical Oncology, 2020, 38, 674-685.	1.6	270
3	Randomized Controlled Trial of Intensity-Modulated Radiotherapy for Early Breast Cancer: 5-Year Results Confirm Superior Overall Cosmesis. Journal of Clinical Oncology, 2013, 31, 4488-4495.	1.6	195
4	A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity. Radiotherapy and Oncology, 2014, 111, 178-185.	0.6	128
5	A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1. Nature Genetics, 2014, 46, 891-894.	21.4	114
6	Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. Radiotherapy and Oncology, 2016, 121, 431-439.	0.6	98
7	Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel. Clinical Cancer Research, 2014, 20, 2466-2475.	7.0	91
8	Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer. EBioMedicine, 2016, 10, 150-163.	6.1	69
9	Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. JAMA Oncology, 2022, 8, e216744.	7.1	51
10	Patient reported outcome measures (PROMs) following forward planned field-in field IMRT: Results from the Cambridge Breast IMRT trial. Radiotherapy and Oncology, 2014, 111, 270-275.	0.6	36
11	Inherited mutations in <i>BRCA1</i> and <i>BRCA2</i> in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls from Malaysia. Journal of Medical Genetics, 2018, 55, 97-103.	3.2	34
12	Prevalence of <i>BRCA1</i> and <i>BRCA2</i> pathogenic variants in a large, unselected breast cancer cohort. International Journal of Cancer, 2019, 144, 1195-1204.	5.1	31
13	A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities. BMC Medicine, 2015, 13, 306.	5.5	26
14	Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer. Cancer Research, 2018, 78, 6329-6338.	0.9	19
15	Breast cancer risks associated with missense variants in breast cancer susceptibility genes. Genome Medicine, 2022, 14, 51.	8.2	19
16	Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity. British Journal of Cancer, 2016, 114, 1165-1174.	6.4	17
17	Patients with a High Polygenic Risk of Breast Cancer do not have An Increased Risk of Radiotherapy Toxicity. Clinical Cancer Research, 2016, 22, 1413-1420.	7.0	16
18	Splicing predictions, minigene analyses, and <scp>ACMG</scp> â€ <scp>AMP</scp> clinical classification of 42 germline <scp><i>PALB2</i></scp> spliceâ€site variants. Journal of Pathology, 2022, 256, 321-334.	4.5	16

Leila Dorling

#	Article	IF	CITATIONS
19	Hereditary breast and ovarian cancer: successful systematic implementation of a group approach to genetic counselling. Familial Cancer, 2017, 16, 51-56.	1.9	15
20	The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study. PLoS ONE, 2016, 11, e0158984.	2.5	15
21	A genome-wide association study of radiotherapy induced toxicity in head and neck cancer patients identifies a susceptibility locus associated with mucositis. British Journal of Cancer, 2022, 126, 1082-1090.	6.4	12
22	First international workshop of the ATM and cancer risk group (4-5 December 2019). Familial Cancer, 2022, 21, 211-227.	1.9	10
23	Rare germline copy number variants (CNVs) and breast cancer risk. Communications Biology, 2022, 5, 65.	4.4	6